When Drug and Therapeutics Bulletin reviews a new medicine, one of our sources of information is the summary of product characteristics (SPC).1 This legal document provides advice about the product, including its unwanted effects and how these might be avoided. When referring to a new medicine, we include a ▼ in the text (see page 30, this issue). The Committee on Safety of Medicines/Medicines Control Agency (CSM/MCA) asks that this symbol be used to indicate when healthcare professionals should use a 'Yellow Card' to report any suspected adverse reaction. Here, we present evidence of weaknesses in the safety aspects of the SPC system and accompanying flaws in the Black Triangle Scheme.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.